You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
Johnson and Johnson
Mallinckrodt
Harvard Business School

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,853,493

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,853,493
Title:Virus induced gene silencing (VIGS) for functional analysis of genes in cotton
Abstract: The invention relates to the functional analysis of genes in cotton by employing the Virus Induced Gene Silencing (VIGS) method. More specifically this method induces gene silencing in cotton with the help of the Tobacco Rattle Virus (TRV) vectors RNA1 and RNA2 and phenotypic effects on the cotton plant can be analysed Moreover this invention also provides transient expression vector TRV RNA2 in order to transiently express genes in cotton plants and plant tissue under the influence of a strong subgenomic promoter.
Inventor(s): Ye; Jian (Singapore, SG), Chua; Nam Hai (Singapore, SG), Qu; Jing (Singapore, SG), Geng; Yun Feng (Singapore, SG), Bu; Yun Ping (Singapore, SG)
Assignee: Temasek Life Sciences Laboratory Limited (Singapore, SG)
Application Number:13/376,902
Patent Claims:1. A method of virus-induced gene silencing (VIGS) in cotton comprising: (a) inserting a nucleic acid comprising a first silencing sequence capable of silencing a first desired gene into a vector comprising a tobacco rattle virus (TRV) RNA2 sequence to produce a vector comprising a modified TRV RNA2 sequence; (b) preparing a mixed culture of Agrobacterium comprising Agrobacterium containing a vector comprising a modified TRV RNA1 sequence and Agrobacterium containing the vector comprising the modified TRV RNA2 sequence, wherein the modified TRV RNA1 sequence is a TRV RNA1 sequence into which an intron has been inserted, wherein the insertion is within positions corresponding to 10919-10922 of SEQ ID NO: 1; (c) introducing the mixed culture of Agrobacterium into plant tissue of cotton to produce infected plant tissue; and (d) growing the infected plant tissue for a sufficient to produce systemic TRV infection in the infected plants and to thereby induce gene silencing of the first desired gene.

2. The method of claim 1, wherein the vector comprising TRV RNA2 and the vector comprising TRV RNA1 are synthetic plant vectors.

3. The method of claim 1, wherein the first silencing sequence is a sequence of a sense strand of the first desired gene.

4. The method of claim 1, wherein the first silencing sequence is a sequence of an antisense strand of the first desired gene.

5. The method of claim 1, wherein the first silencing sequence encodes a short hairpin RNA (shRNA) or a precursor microRNA (miRNA).

6. The method of claim 1, wherein the nucleic acid further comprises a second silencing sequence capable of silencing a second desired gene.

7. The method of claim 1, wherein the nucleic acid comprises multiple silencing sequences capable of silencing multiple desired genes.

8. The method of claim 1, wherein the desired gene is a candidate transcription factor gene.

9. The method of claim 1, wherein the desired gene is a candidate gene in smRNA biosynthesis.

10. The method of claim 1, wherein the desired gene is selected from the group consisting of (a) a candidate gene in a proanthocyanidin or anthocyanidin biosynthetic pathway, (b) a candidate gene in cotton fiber development, (c) a candidate gene in a chlorophyll or arotenoid biosynthetic pathway and (d) a candidate gene in a flavonoid biosynthetic pathway.

11. The method of claim 10, wherein the candidate gene in cotton fiber development is a candidate gene in cotton fiber initiation, elongation, secondary wall deposition, maturation or seed development.

12. The method of claim 1, wherein the cotton tissue is a cotton plant, a cotton seedling, a cotton ovule or cotton fiber.

13. The method of claim 1, wherein the cotton is a diploid variety, a tetraploid variety, a variety of an inter-species cross or a variety of an interspecies cross.

Summary for Patent:   Start Trial

PCT Information
PCT FiledJune 10, 2010PCT Application Number:PCT/SG2010/000220
PCT Publication Date:December 16, 2010PCT Publication Number:WO2010/144058

Details for Patent 8,853,493

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Temasek Life Sciences Laboratory Limited (Singapore, SG) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Temasek Life Sciences Laboratory Limited (Singapore, SG) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Temasek Life Sciences Laboratory Limited (Singapore, SG) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
AstraZeneca
Moodys
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.